Outcomes of combination therapy for stage IIA–IIIB cervical cancer
D.-K. Reyes SantiagoSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of RussiaА. С. ХаджимбаSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of RussiaИван Викторович СоболевSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of RussiaА. А. IlyinSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of RussiaS. Ya. MaksimovSaint Petersburg Clinical Research Center for Specialized Medical Care (Oncology), Ministry of Health of Russia
2018en
ABI
Annotatsiya
Objective: to analyze treatment outcomes in patients with stage IIA–IIIB cervical cancer.Materials and methods. The study included 278 women with stage IIA–IIIB cervical cancer. Study participants were divided into 2 groups. Group 1 comprised 165 patients who received chemoradiotherapy + surgery (radical hysterectomy). Patients in group 2 received standard radiotherapy.Results. Patients receiving combination therapy demonstrated better overall and relapse-free survival compared to those receiving standard treatment.Conclusion. Both publications of other authors and our own results suggest high efficacy and safety of combination therapy for stage IIA–IIIB cervical cancer.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba